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Summary
Background Epidemiological evidence suggests that hookworm infection protects against
asthma. However, for ethical and safety reasons, before testing this hypothesis in a clinical
trial in asthma it is necessary to establish whether experimental hookworm infection might
exacerbate airway responsiveness during larval lung migration.
Objective To determine whether hookworm larval migration through the lungs increases
airway responsiveness in allergic individuals with measurable airway responsiveness but not
clinical asthma, and investigate the general tolerability of infection and effect on allergic
symptoms.
Methods Thirty individuals with allergic rhinoconjunctivitis and measurable airway
responsiveness to adenosine monophosphate (AMP) but not clinically diagnosed asthma
were randomized, double-blind to cutaneous administration of either 10 hookworm larvae or
histamine placebo, and followed for 12 weeks. The primary outcome was the maximum fall
from baseline in provocative dose of inhaled AMP required to reduce 1-s forced expiratory
volume by 10% (PD10AMP) measured at any time over the 4 weeks after active or placebo
infection. Secondary outcomes included peak ﬂow variability in the 4 weeks after infection,
rhinoconjunctivitis symptom severity and adverse effect diary scores over the 12-week study
period, and change in allergen skin test responses between baseline and 12 weeks.
Results Mean maximum change in PD10AMP from baseline was slightly but not signiﬁcantly
greater in the hookworm than the placebo group ( 1.67 and  1.16 doubling doses; mean
difference  0.51, 95% conﬁdence interval  1.80 to 0.78, P=0.42). Symptom scores of
potential adverse effects were more commonly reported in the hookworm group, but infection
was generally well tolerated. There were no signiﬁcant differences in peak-ﬂow variability,
rhinoconjunctivitis symptoms or skin test responses between groups.
Conclusion Hookworm infection did not cause clinically signiﬁcant exacerbation of airway
responsiveness and was well tolerated. Suitably powered trials are now indicated to determine
the clinical effectiveness of hookworm infection in allergic rhinoconjunctivitis and asthma.
Keywords airway responsiveness, allergic rhinoconjunctivitis, allergy, hayfever, helminth,
hookworm, intervention, Necator americanus
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Introduction
Almost 800 million people are currently infected with
hookworm [1]. Although high levels of hookworm infec-
tion can cause signiﬁcant morbidity and mortality, there
is mounting evidence from epidemiological studies that
infection is also associated with a reduced risk of asthma
[2] and other allergic disorders [3, 4]. This raises the
possibility that hookworm infection, particularly at levels
of intensity above the threshold of about 50eggs/g of
faeces at which the reduction in risk of wheeze appears to
be most marked [5], may also have a therapeutic effect in
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provide an opportunity for the development of new
treatment options for this disease [6, 7]. Testing this
hypothesis, however, requires ﬁrst, establishment of the
dose of hookworm required to generate the necessary
intensity of infection; and second, conﬁrmation that
infection is sufﬁciently safe and well tolerated to make
clinical trials feasible. It is also important to determine
whether infection induces a natural immune phenotype. A
particular safety concern is the possibility of an increase
in airway responsiveness during migration of hookworm
larvae through the lungs, which typically occurs within
4 weeks of infection [8] and stimulates eotaxin release and
a peripheral blood and pulmonary eosinophilia [9], and
could therefore cause exacerbation of asthma.
In a pilot study of healthy volunteers, we have estab-
lished that infection with 10 Necator americanus larvae
achieved an infection intensity of over 50eggs/g of
faeces, and in the small number of participants involved,
was well tolerated [7]. We now report a safety study,
performed in the UK and comprising a randomized,
placebo-controlled, double-blind trial of hookworm in-
fection in people with allergic rhinoconjunctivitis without
clinical symptoms of asthma, but with measureable air-
way responsiveness to adenosine monophosphate (AMP)
below a threshold considered to be indicative of asthma.
The study was designed to determine whether hookworm
infection exacerbates airway responsiveness at any time
during the ﬁrst 4 weeks after infection. Our secondary
objectives were to assess the tolerability of infection and
to observe the effect of infection on peak ﬂow variability,
rhinoconjunctivitis symptom severity and allergen skin
test responses over a 12-week period.
Materials and methods
Study participants
Study participants aged 18 years and over with current
symptoms of allergic rhinoconjunctivitis were recruited by
local advertisement. After excluding those with a diagno-
sis ofasthma orothersigniﬁcantmedicaldisorder, and any
women who were pregnant or unwilling to use contra-
ception for the duration of the study, potential participants
were invited to attend a screening visit. Recruitment
occurred between February and August 2006.
Screening visit
At the screening visit, the study protocol was explained
and written informed consent obtained. Lung function
was measured according to international guidelines [10]
using a spirometer (Vitalograph, Buckingham, UK) taking
the 1-s forced expiratory volume (FEV1) as the higher of
two values within 100mL. Subjects were excluded if the
FEV1 was less than 80% predicted when compared with
standard reference ranges [11]. AMP challenge was carried
out by inhaling an initial dose of 0.9% saline control,
followed by doubling doses (DD) of AMP (Sigma Chemical
Co., Poole, Dorset, UK) dissolved in 0.9% saline from 0.115
to 944mM from a breath-activated dosimeter (MEFAR,
Brescia, Italy) set to nebulize for 1s with a pause of 6s at a
pressure of 152kPa. FEV1 was measured 2min after each
dose. We initially intended to measure airway responsive-
ness using the provocation dose of AMP required to reduce
FEV1 by 20% (PD20A M P ) ,b u tf o u n di nt h ec o u r s eo f
recruiting for the study that very few volunteers demon-
strated this degree of airway responsiveness. We therefore
elected to adopt the PD10 measure, as this was more easily
demonstrable and has been shown to strongly predict PD20
[12]. The inhalation challenge was therefore stopped once
FEV1 had fallen by 10% from the post-saline baseline value,
or the maximum dose of AMP had been inhaled [13], and
the PD10AMP calculated by interpolation between the two
last doses on the log dose–response scale [10]. Subjects who
did not achieve a fall in FEV1 of 10% during the bronchial
challenge were excluded from the study.
Venous blood was taken for haemoglobin estimation,
differential cell counting, serum albumin and hookworm
serology analysis, and participants excluded if they were
anaemic or had evidence of past or current hookworm
infection. Allergen skin sensitization to Dermatopha-
goides pteronyssinus, cat fur, grass pollen and histamine
and saline controls (Diagenics Ltd, Milton Keynes, UK)
was measured by standard skin prick test methods [14],
with a positive result deﬁned as a mean whal diameter
3mm greater than the saline control. Subjects without at
least one positive result to the three allergen solutions
were excluded. Urine analysis for b-HCG (QuickVue,
Quidel Corporation, San Diego, CA, USA) was used to
conﬁrm that female participants of child-bearing age
were not pregnant. An interviewer-administered Juniper
Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ)
[15] was completed to ensure that subjects had current
symptoms and to establish a baseline symptom score.
Randomization
Subjects fulﬁlling the entry criteria and who consented to
enrolment in the study were seen 1 week later for double-
blind randomization to active or placebo infection, allo-
cated in blocks of four according to a computer generated
random code. Ten N. americanus (L3) larvae in 200mLo f
water (active infection) or 200mL histamine dihydrochlor-
ide solution (1.7mg/mL) (placebo) were administered to
an area of skin on the forearm and covered with gauze and
a water-tight adhesive dressing, which were kept in place
for 24h. The larvae were obtained by a culture of faecal
material from a healthy human source known to be
negative for hepatitis B and C and human
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Safety study of hookworm infection 1061immunodeﬁciency virus as described previously [16]. The
solutions were administered by an independent member
of the research team who was not involved in any of the
study measurements, to ensure that the clinical researcher
carrying out the protocol measures remained blind to the
treatment allocation.
Follow-up visits
Following randomization, participants were seen by the
clinical researcher every week for 4 weeks, then every 2
weeks for a further 8 weeks. To maintain blinding of the
clinical researcher, subjects were asked to cover their arm
at the site of the dressing application during these visits in
case of local skin redness and to discuss any queries
relating to the study with a different member of the
research team. At each study visit, including the rando-
mization visit, PD10AMP was measured as described pre-
viously, a Juniper RQLQ completed, and blood taken for
haemoglobin, differential cell counts and albumin estima-
tion. To assess the immune phenotype, leucocytes sub-
types were determined by ﬂow cytometry, and cytokine
and chemokine responses to infection assessed following
T cell stimulation. Serological responses to the parasite
were assessed by ELISA and western blotting and IgE
responses to cat, D. pteronyssinus and mixed grass pollens
determined to eliminate parasite potentiation of bystander
allergic responses; these data will be reported separately.
A stool sample collected within 24h of the visit was
provided, and egg content quantiﬁed as described else-
where [7]. In the week preceding randomization, and for
the duration of the study, participants completed a daily
diary, recording morning and evening peak expiratory
ﬂow rates (PEFR; measured as the best of three attempts)
and a symptom score based on a visual analogue scale
from 0 (no symptoms) to 10 (maximum possible severity
of symptoms) for a range of pre-determined possible
adverse effects due to the hookworm. These included skin
reactions at the site of infection, tiredness, gastrointestinal
and respiratory symptoms. Participants also recorded any
use of medication for allergic rhinoconjunctivitis. At the
ﬁnal visit, 12 weeks after randomization, allergen skin
tests were repeated. Participants were then unblinded by
the researcher who administered the infection or placebo
at their randomization visit, and those in the hookworm
group given a standard course of mebendazole to eradi-
cate the infection. Stool egg counts and blood eosinophil
counts were checked every 2 weeks until egg counts were
zero and eosinophils had returned to within normal
reference ranges on two successive occasions.
Medication use
Participants were asked to abstain from the use of anti-
histamines and steroid nasal sprays for the duration of the
study whenever possible. Where occasional usage of
antihistamines was unavoidable, participants were pro-
vided with a supply of loratidine 10mg tablets to standar-
dize the antihistamine used, and were instructed to record
use in their daily diary. A small proportion of participants
requested to take antihistamines on a daily basis due to
the severity of their symptoms; and these were asked to
substitute their usual medication with loratidine 10mg
taken once daily for the duration of the whole study
period; similarly, one participant took a daily steroid nasal
spray throughout the entire study.
Safety and ethics
Data on adverse effects and haemoglobin, eosinophil and
albumin levels were monitored as the study progressed by
the trial statistician and a study safety committee with
a priori guidelines on when to withdraw a participant
from the study. The study was reviewed and approved by
the Nottingham Research Ethics Committee and Research
and Development department at the Nottingham Univer-
sity Hospitals NHS Trust.
Data analysis
The primary outcome variable was the maximum fall
in log PD10AMP occurring at any time between weeks 1
and 4 after randomization from the value at baseline,
expressed in doubling doses. We intended to deﬁne the
baseline measurement as the mean of the two pre-
infection values (screening and week 0); however, because
of the learning process that was observed in performing
the bronchial challenge, we had concern that the values
obtained at the screening visit were not reliable and
therefore used the week 0 value as the baseline for the
primary analysis. However, the results using the mean of
screening and week 0 values as baseline were also
computed for comparison. PEFR variability during the
ﬁrst 4 weeks after infection was computed as the
two-lowest % mean (mean of the two lowest PEFR
values during this period as a percentage of the period
mean) [17].
An allergic symptom score was computed at each visit
by summing individual symptoms recorded on the Juniper
RQLQ (maximum score 168), and summarized over the
12-week study period using area under the curve (AUC)
(GraphPad Prism 4, GraphPad Software Inc., San Diego,
CA, USA). Change in allergen skin sensitization was
computed for each allergen by subtracting the baseline
saline-adjusted skin prick result in millimetres from the
week 12 result. For each potential adverse effect, the mean
daily score was computed for boththe whole 12 weeks and
also a pre-determined ‘high-risk’ period chosen as the
period during which time we predicted the symptoms were
most likely to occur. These periods were days 1–21 for
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[7], days 1–28 for respiratory symptoms coinciding with
the period of larval lung migration in the hookworm
lifecycle [8], and days 29–70 for gastrointestinal symp-
toms and tiredness correlating with the period of elevated
eosinophil counts which can result in an eosinophilic
gastroenteritis [18]. This was to ensure that the magnitude
of effect of important adverse symptoms was not diluted
by averaging over the full 12 weeks of the study.
All data were analysed using in SPSS version 14.0
(SPSS Inc., Chicago, IL, USA). With the exception of those
for adverse effects, all variables were compared between
the two groups using the independent samples t-test, and
multiple linear regression used to adjust for any baseline
differences in demographics. The PEFR analysis was
repeated excluding any participants who had provided
less than 75% of potential readings during the ﬁrst 4
weeks. The logarithm of the Juniper RQLQ AUC variable
was taken to obtain a normal distribution and multiple
linear regression carried out to additionally adjust for
baseline values. The analysis was repeated excluding
participants who used antihistamines more than three
times per week (unless used daily). Adverse effects vari-
ables were not normally distributed and could not be
transformed, so the two groups were compared using the
non-parametric Mann–Whitney U-test.
Our primary objective was to detect a clinically signiﬁ-
cant increase in airway responsiveness, which we deﬁned a
priori to be of one doubling dose or more in magnitude, in
the active relative to the placebo group. We estimated that a
sample size of 30 (15 in each group) would provide
approximately 80% power to detect a difference of this
magnitudeinthemaximumfallinPD10AMPbetweenactive
and placebo groups, assuming a similar repeatability to that
reported for PD20AMP [13, 19].
Results
Thirty people participated in the study: 15 were rando-
mized to active hookworm infection and 15 to placebo
(Fig. 1). There were more current smokers in the placebo
group, but otherwise, the demographic characteristics of
the two groups were similar (Table 1). Three participants
withdrew from the study and were subsequently un-
blinded: one from the placebo group on day 6 due to an
inter-current viral illness; one from the hookworm group
on day 12 after becoming pregnant despite a negative
pregnancy test at entry into the study and use of contra-
ception; and one from the hookworm group on day 40
due to abdominal pain and diarrhoea, and was treated
with mebendazole to eradicate the infection (Fig. 1).
The participant who withdrew because of pregnancy kept
the infection and completed an otherwise uneventful and
successful pregnancy. Exclusion of data from these
individuals did not appreciably change the overall
demographic characteristics of the two groups. Four
participants were unable to attend the week 12 visit and
were therefore seen at the earliest possible occasion which
was during week 13 for three of them and week 16 (day
112) for one.
Airway responsiveness
Data on airway responsiveness over the ﬁrst for 4 weeks
following randomization were available for 28 partici-
pants. The mean of the maximum fall in PD10AMP during
this period was slightly greater in the hookworm than the
placebo group ( 1.67 and  1.16 DD, respectively), but the
difference between the groups was small ( 0.51 DD, 95%
CI  1.80 to 0.78) and not statistically signiﬁcant either
before or after adjusting for the baseline difference in
smoking status (P=0.42 and 0.34, respectively, Table 2).
The individual maximum changes ranged from  5.55 to
0.81 DD in the hookworm group and  4.26 to 1.47 DD in
the placebo group. Peak ﬂow variability over the ﬁrst 4
weeks was slightly less (i.e. closer to 100%) in the hook-
worm group compared with placebo, but not signiﬁcantly
so (adjusted mean difference 3.62%, 95% CI  0.66 to
7.90%) (Table 2).
Screened
n=54
Excluded
n=24
Eligible
n=30
Placebo
n=15
Hookworm
n=15
Drop-out
n=1
Drop-out
n=2
Completed
n=14
Completed
n=13
Fig. 1. Flow chart of study participants.
Table 1. Demographics and baseline characteristics of study participants
Hookworm
(n=15)
Placebo
(n=15)
Males (%) 9 (60) 9 (60)
Mean age (years) at entry (SD) 30.3 (8.97) 33.2 (8.82)
Current smoker (%) 3 (20) 6 (40)
Caucasian (%) 13 (87) 15 (100)
Median PD10AMP at screening
(IQR)
13.3 (4.3, 48.3) 24.8 (9.2, 68.8)
Median PD10AMP at week 0 (IQR)
w 19.8 (6.4, 52.1) 42.1 (23.6, 102.2)
n=13 for each group.
wn=14 for hookworm group, n=13 for placebo group.
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The hookworm group reported more symptoms of rhino-
conjunctivitis over the 12-week study period than the
placebo group, but again this difference was small and not
statistically signiﬁcant either before or after adjustment
for smoking and baseline score (Table 3), or after exclud-
ing those who had used antihistamines on more than three
occasions in a 1 week period (unless taken daily; adjusted
mean difference log AUC 0.42, 95% CI  0.49 to1.32).
There was no signiﬁcant difference in change in the
magnitude of the wheal response to any of the individual
allergens tested (Table 3). The conﬁdence intervals for all
these outcomes did not exclude a beneﬁcial effect.
Adverse effects
Table 4 shows the reported symptom scores for the
potential adverse effects attributable to the hookworm.
Table 2. Respiratory outcomes measured over the ﬁrst 4 weeks following randomization
Hookworm mean
(SD) (n=14)
Placebo mean
(SD) (n=14)
Mean difference
(95% CI) P-value
Adjusted mean
difference (95% CI) P-value
Change in bronchial reactivity using week 0 as
baseline (DD PD10AMP)
 1.67 (1.72)  1.16 (1.60)  0.51 ( 1.80, 0.78) 0.42  0.63 ( 1.97, 0.70) 0.34
Change in bronchial reactivity using mean
of screening and week 0 values as baseline
(DD PD10AMP)
 1.52 (1.55)  0.62 (1.92)  0.89 ( 2.25, 0.46) 0.19  0.99 ( 2.40, 0.43) 0.16
Peak ﬂow variability (Two-lowest % mean) 92.31 (3.73) 89.30 (6.70) 3.01 ( 1.21, 7.22) 0.15 3.62 ( 0.66, 7.90) 0.09
Adjusted for smoking status; SD, standard deviation; 95% CI, 95% conﬁdence interval.
Table 3. Allergic outcomes measured over the 12-week study period
Hookworm mean
(SD) (n=13)
Placebo mean
(SD) (n=14)
Mean difference
(95% CI) P-value
Adjusted mean
difference (95% CI) P-value
Juniper RQLQ score (log AUC) 6.01 (0.82) 5.68 (0.85) 0.33 ( 0.33, 1.00) 0.31 0.26 ( 0.45, 0.97) 0.46
Change in grass SPT reaction (mm) 0.73 (2.65) 0.11 (2.65) 0.62 ( 1.48, 2.73) 0.55 1.18 ( 0.94, 3.30) 0.26
Change in cat fur SPT reaction (mm)  0.27 (2.09)  0.75 (1.83) 0.48 ( 1.07, 2.03) 0.53 0.64 ( 1.01, 2.29) 0.43
Change in DP SPT reaction (mm) 1.27 (2.19) 0.54 (2.59) 0.74 ( 1.18, 2.64) 0.44 0.85 ( 1.19, 2.90) 0.40
All adjusted for smoking status; Juniper RQLQ additionally adjusted for baseline score.
95% CI, 95% conﬁdence interval; DP, Dermatophagoides pteronyssinus.
Table 4. Adverse effects reported in subjects with and without hookworm infection
Symptoms
Mean daily score (scale 0–10) over total 12-week period Mean daily score (scale 0–10) over high-risk period
w
Median (range) Median (range)
Hookworm
group
Placebo
group
Difference
in medians P-value
Hookworm
group
Placebo
group
Difference
in medians P-value
Localized skin itching 0.30 (0.05–1.10) 0 (0–1.32) 0.30 0.003 1.12 (0.19–3.11) 0 (0–1.76) 1.12 0.001
Localized skin redness 0.22 (0.02–1.04) 0 (0–0.48) 0.22 0.001 1.02 (0.10–5.00) 0 (0–1.90) 1.02 o0.001
Wheeze 0.30 (0–1.11) 0.07 (0–0.98) 0.23 0.14 0.36 (0–2.07) 0.14 (0–2.00) 0.22 0.29
Cough 0.22 (0–1.02) 0.10 (0–1.54) 0.12 0.56 0.43 (0–1.35) 0.11 (0–2.79) 0.32 0.30
Breathlessness 0.14 (0–6.04) 0 (0–0.98) 0.14 0.07 0.05 (0–5.14) 0 (0–1.86) 0.05 0.34
Nausea 0.17 (0–2.45) 0 (0–1.85) 0.17 0.10 0 (0–4.72) 0 (0–2.07) 0 0.13
Diarrhea 0.12 (0–3.37) 0.11 (0–3.88) 0.01 0.59 0.06 (0–5.64) 0.06 (0–3.95) 0 0.84
Abdominal pain 0.24 (0–3.81) 0.02 (0–3.00) 0.22 0.06 0.48 (0–5.92) 0 (0–3.64) 0.48 0.06
Flatulence 0.28 (0–1.76) 0.13 (0–2.62) 0.15 0.36 0.31 (0–1.98) 0.05 (0–3.05) 0.26 0.16
Indigestion 0.11 (0–2.39) 0 (0–0.87) 0.11 0.02 0.10 (0–3.92) 0 (0–1.19) 0.10 0.03
Loss of appetite 0.14 (0–2.25) 0.03 (0–2.21) 0.11 0.67 0.24 (0–4.28) 0 (0–2.60) 0.24 0.30
Tiredness 0.86 (0–6.34) 0.14 (0–2.99) 0.72 0.25 0.41 (0–6.55) 0.15 (0–2.93) 0.26 0.51
Po0.05 (P-value for Mann–Whitney U-test).
wHigh-risk periods: localized skin symptoms (days 1–21), respiratory symptoms (days 1–28), gastrointestinal symptoms and tiredness (days 29–70).
Range=minimum–maximum.
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higher in the hookworm group compared with placebo
group, particularly during the high risk period [difference
in medians for mean daily score 1.02 (P=0.001) and 1.12
(Po0.001), respectively; Table 4 and Fig. 2]. These symp-
toms peaked in the hookworm group in the ﬁrst week with
some subjects experiencing a second, less marked peak, in
week 2 as previously described [7]. For the non-skin
symptoms, there was more of a range of different partici-
pant experiences with many reporting mean daily scores
of zero (i.e. no symptoms). Scores tended to be higher in
the hookworm than the placebo group but the magnitude
of the differences were fairly small. A signiﬁcant differ-
ence was seen for indigestion (difference in medians 0.1,
P=0.03) during the high-risk period, and a borderline
signiﬁcant effect was seen for abdominal pain (difference
in medians 0.48, P=0.06). Breathlessness was also higher
in the hookworm group but not statistically so, and during
the high-risk period this difference was even less marked.
Notably, there was no difference between the two groups
of the other respiratory symptoms (Table 4).
All participants had haemoglobin and albumin levels
within the normal ranges at entry into the study. No
clinically important falls in haemoglobin were seen in
either group, with the maximum fall in haemoglobin from
baseline being 1.4g/dL in the hookworm group and 0.8g/
dL in the placebo group. Similarly, there was no sugges-
tion of any signiﬁcant changes in serum albumin levels
with the greatest fall from baseline being 7g/dL in both
groups, to a minimum of 36g/dL and 31g/dL in the
hookworm and placebo groups, respectively.
Effect on eosinophil levels
Twelve of the 13 participants in the hookworm group who
completed the study had a rise in eosinophil counts, which
typically started between 21 and 28 days after infection
and reached a peak at weeks 6–8 (days 42–56) (Fig. 3) with
maximum counts ranging from 1.53 10
9 to 9.70 10
9L
 1.
All eosinophil counts decreased after this time but had not
returned to baseline values by the end of the study at week
12 (day 84) (Fig. 3). The change in eosinophil counts was
reﬂected by a rise in total white cell counts, which also
peaked during this time with a maximum eosinophilia (%
eosinophil count/total white cell count) ranging between
21% and 60%; no change was seen in numbers of any
other leucocyte type. There was no rise in the eosinophil
counts in any of participants in the placebo group.
Egg counts
Eggs were found in faecal samples of nine participants in
the hookworm group, appearing at either week 6 (six
people) or 8 (three people) after infection. The presence of
these eggs was conﬁrmed by culturing faecal material
obtained at week 12 to detect presence of infective larvae.
Three of the four participants in the hookworm group with
negative stool samples had a rise in their eosinophil count
(peaks of 3.3–9.6 10
9L
 1), implying that the hookworm
larvae had reached the bowel and successfully developed
into adult worms. In all nine participants with positive
samples, greater than 50eggs/g of faeces were found on
each occasion. Eggs were not seen in any participants in
the placebo group. Repeating our primary outcome ana-
lysis after excluding the four subjects without eggs in
their faeces yielded similar results (mean change in DD
PD10AMP for hookworm group  0.62: adjusted mean
difference  0.81, 95% CI  2.12 to 0.51).
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Fig. 2. Skin symptoms measured on a visual analogue scale (0–10) over
the ﬁrst 4 weeks after randomization: (a) skin redness, (b) skin itching.
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Safety study of hookworm infection 1065Assessment of subject blinding
All participants were asked at their ﬁnal study visit, before
being unblinded, if they thought they knew whether they
had received hookworm or placebo infection. Of the 14
individuals in the placebo group who completed the study,
three correctly thought they had received placebo, ﬁve
that they had received hookworm, and six did not know.
Of the 13 with hookworm infection who completed the
study, eight correctly thought that they had received
hookworm, two thought they had received placebo, and
three did not know.
Follow-up
All participants who received hookworm were provided
with mebendazole at the end of the study to eradicate the
infection. However, 11 of the 13 participants who com-
pleted the study chose not to take the treatment, citing
either a perceived improvement in hayfever symptoms, or
that they wished to see if they had a change in symptoms
the following year. In accordance with our protocol,
participants in the placebo group were offered hookworm
infection at the end of the trial, of whom 11 chose to be
infected.
Discussion
To our knowledge, this is the ﬁrst reported randomized
placebo-controlled double-blind study of hookworm infec-
tion in people with allergic disease. The study was carried
out in preparation for a therapeutic trial in asthma, in
accordance with our ethics submission and approval, to
look for evidence of any clinically important increase in
airway responsiveness during lung migration of larvae. We
used the dose we have shown to be well tolerated and which
results in an infection intensity of over 50eggs/g of faeces
[7], and which in turn was associated with a reduced risk of
wheeze in our observational study [5]. We studied partici-
pants with allergic rhinoconjunctivitis and measurable air-
way responsiveness, but without clinical asthma [20], so
that we could look for an increase in airway responsiveness
in the active treatment group while minimizing the risk of
serious clinical exacerbation of asthma. Participants were
also monitored for any symptoms potentially attributable to
the hookworm infection. In addition, although designed and
powered to detect effects on airway responsiveness, our
study also provided an opportunity to explore the effect of
infection on rhinoconjunctivitis symptom severity and
allergen skin sensitivity.
The procedures we adopted to ensure that participants
and clinical investigators remained blind to treatment
allocation were successful for the investigator, and pre-
dominantly so for participants. Most of those participants
who did correctly guess their treatment allocation were in
the active treatment group, and usually based their judg-
ment on seeing entry portals on their arm after infection,
or the presence of gastrointestinal disturbance. The hista-
mine solution used as a placebo did cause local redness
and itching as reﬂected in the adverse symptoms scores,
but this lasted for a shorter period than the local symp-
toms due to hookworm. We were able to conﬁrm hook-
worm infection by the presence of eggs in faeces for nine
of our infected group, and of the other six participants
randomized to hookworm, two withdrew before eggs were
expected to be seen in faeces, and three demonstrated
increases in eosinophil counts similar to those with
proven infection, suggesting that they were actively
infected but with same-sex organisms or with non-fecund
females. It therefore appears that our infection process
failed in only one participant in the hookworm group in
whom there was no evidence of active infection. However,
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Fig. 3. Individuals’ peripheral blood eosinophil counts over the 12-week
study period: (a) hookworm group, (b) placebo group.
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egg counts from the analyses had no material impact on
the ﬁndings of the study.
The larval pulmonary migration phase of the N. amer-
icanus lifecycle typically occurs during the ﬁrst 4 weeks
after infection. The stage 3 larvae travel via the blood
circulation until they reach the pulmonary vasculature;
here, they cross into the alveoli, migrate up the proximal
airways, are expectorated and then swallowed. Once in the
duodenum, they mature to reach adult status at around 6–8
weeks after infection [21]. While there is some evidence that
other intestinal helminths, such as Ascaris,m a ya c t u a l l y
exacerbate asthma symptoms [22, 23] and that this may be
reversed by parasite eradication therapy [24], asthma ex-
acerbation does not appear to be a problem with hookworm
infection [2]. However, studies in animals have demon-
strated a pronounced Th2 phenotype associated with this
phase of the lifecycle [9, 25], indicating that exacerbation of
clinical disease may occur. Furthermore, bronchoscopic
investigation before and during larval pulmonary migration
in four normal volunteers who had each received 50
infective N. americanus larvae demonstrated bronchial
mucosal erythema and in one case elevated eosinophils in
bronchoalveolar lavage ﬂuid [26]. We therefore felt it
essential to carry out an assessment of the effect of hook-
worm infection on airway responsivenessbefore proceeding
to a clinical trial in asthma.
Because it is not possible to predict when lung migra-
tion will take place in any individual subject, we used the
largest observed increase in airway responsiveness at any
time during the ﬁrst 4 weeks after infection as our primary
outcome. We observed a small increase in airway respon-
siveness in the hookworm group relative to placebo,
estimated to be less than one doubling dose of AMP in
magnitude, but this effect was not statistically signiﬁcant.
Furthermore, this size of effect is unlikely to be clinically
signiﬁcant considering the magnitude of normal repeat-
ability for airway responsiveness to bronchial challenge
testing is large (95% conﬁdence limits of approximately
 1.5 doubling doses for 2-week repeated challenge to
methacholine) [10]. The magnitude of effect we observed
is also less than that seen to be associated with established
therapies for asthma [27, 28]. During the screening visits,
we observed that certain participants took some time to
learn how to use the dosimeter properly resulting in
unreliable screening measurements of their bronchial
responsiveness. We therefore elected to use the week 0
results as the baseline measurement for our primary
analysis but also presented the results using the mean of
the screening and week 0 values as baseline as per
protocol (Table 2). In the hookworm group, the resulting
mean value of the primary outcome variable, maximum
fall in PD10 was similar using the two different deﬁnitions
for baseline, but less so in the placebo group where the
mean value was lower when the deﬁnition included the
screening data ( 0.62 DD) than when based on week 0 data
alone ( 0.16 DD; Table 2). Further exploration revealed that
this discrepancy was primarily due to one individual who
responded rapidly to AMP at screening and thus had a very
low value, but who had a much higher value at week 0;
exclusion of this subject from the analysis resulted in a
similar estimated mean difference between hookworm and
placebo groups regardless of baseline deﬁnition ( 0.51 DD
using week 0 as baseline and  0.55 using mean of screening
and week 0). In addition, neither results for peak-ﬂow
variability, northe reporting of respiratory symptoms showed
any evidence to suggest that hookworm infection increased
airway responsiveness and thus indicates that infection with
10 larvae is unlikely to exacerbate asthma. The adverse
effects reported by participants who were infected with
hookworm were principally skin itching and gastrointestinal
disturbance, and in the majority of cases were mild with only
one person choosing to withdraw from the study as a
consequence. Our study thus indicates that this level of
infection is likely to be tolerated by the majority of partici-
pants in trials, and that exacerbation of asthma is unlikely.
Previous observational studies have suggested that
allergic rhinoconjunctivitis is less common in individuals
infected with intestinal parasites [29, 30], and an early
anecdotal report described an improvement in hayfever
symptomsafterself-infection[31].Ourstudydidnotdetect
evidence of a signiﬁcant improvement in rhinoconjuncti-
vitis symptoms or allergen skin test responses in the
infected group relative to the controls, but was not
powered or speciﬁcally designed to do so; our objective
was to identify clinically relevant exacerbation of airway
responsiveness. Furthermore, some evidence indicates that
helminth infection after allergen exposure may actually
lead to a potentiated allergic response and a possible
worsening of symptoms as a result, and therefore, in order
to suppress allergy would require helminth infection to
precede allergen exposure [32, 33]. We did not make
allowance for this in the design of our study, but because
we have demonstrated that hookworm infection did not
potentiate IgE responses to the environmental allergens to
which the subjects were sensitized (data not shown). An
exploratory analysis of the effects of infection on immune
regulation will be reported elsewhere. The clinical effec-
tiveness of hookworm infection in allergic rhinitis there-
fore needs to be tested in larger studies, in which infection
is timed to precede the advent of seasonal allergy, though
clinical trials in adults may still show no effect if the
protective effect of hookworm infection described in ob-
servational studies arises from infection in the early years
of life rather than current infection in adults with an
already established allergic phenotype. However, the ﬁnd-
ings of this trial indicate that further deﬁnitive trials are
feasible and likely to be well tolerated, and that it is also
safetoproceed with studiestodetermine whetherinfection
is effective in the management of asthma.
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